炎症
医学
疾病
免疫系统
免疫学
Toll样受体
先天免疫系统
受体
卡那努马布
糖尿病
伤亡人数
生物信息学
生物
内科学
内分泌学
阿纳基纳
作者
Ying Zhou,Peter J. Little,Liam Downey,Rizwana Afroz,Yuao Wu,Hang T. Ta,Suowen Xu,Danielle Kamato
出处
期刊:ACS pharmacology & translational science
[American Chemical Society]
日期:2020-02-06
卷期号:3 (3): 457-471
被引量:28
标识
DOI:10.1021/acsptsci.9b00100
摘要
Toll-like receptors (TLRs) are dominant components of the innate immune system. Activated by both pathogen-associated molecular patterns and damage-associated molecular patterns, TLRs underpin the pathology of numerous inflammation related diseases that include not only immune diseases, but also cardiovascular disease (CVD), diabetes, obesity, and cancers. Growing evidence has demonstrated that TLRs are involved in multiple cardiovascular pathophysiologies, such as atherosclerosis and hypertension. Specifically, a trial called the Canakinumab Anti-inflammatory Thrombosis Outcomes Study showed the use of an antibody that neutralizes interleukin-1β, reduces the recurrence of cardiovascular events, demonstrating inflammation as a therapeutic target and also the research value of targeting the TLR system in CVD. In this review, we provide an update of the interplay between TLR signaling, inflammatory mediators, and atherothrombosis, with an aim to identify new therapeutic targets for atherothrombotic CVD.
科研通智能强力驱动
Strongly Powered by AbleSci AI